Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach.
By H. Bays, Lawrence J. Mandarino, Ralph DeFronzo. Journal of Clinical Endocrinology and Metabolism, 2004
683 citations recorded by the source corpus.
Subfields: Epidemiology, Molecular Biology, Physiology
View Paper: https://www.semanticscholar.org/paper/9b066ba4dc0df2936c0e41047eea6a21441f6247
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
- B. Spiegelman
- Mitchell A. Lazar
- Ralph DeFronzo
- Christopher K. Glass
- Johan Auwerx
- Takashi Kadowaki
- Haiming Cao
- I. Tabas
In Molecular Biology
- Ralph DeFronzo
- Mitchell A. Lazar
- Johan Auwerx
- Muhammad Abdul-Ghani
- B. Spiegelman
- L. Michalik
- W. Wahli
- Bart Staels
In Physiology
- B. Spiegelman
- Johan Auwerx
- Ralph DeFronzo
- Mitchell A. Lazar
- L. Michalik
- W. Wahli
- Muhammad Abdul-Ghani
- S. O’Rahilly
Citations in the corpus
- International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors (2006, background): “Among the synthetic compounds that selectively activate PPAR , the thiazolidinediones are insulin sensitizers used to treat the hyperglycemia of type 2 diabetes (Mayerson et al., 2002; Bajaj et al., 2003; Bays et al., 2004).”
- Pathogenesis of Insulin Resistance in Skeletal Muscle (2010, background): “The important role of elevated plasma FFA in the pathogenesis of insulin resistance is now well established [12, 14, 57].”